Immunotherapy: Magic Bullet to Change the Future Therapeutics

1st Edition, Volume 144 - February 24, 2025
Imprint: Academic Press
Editors: Vijay Kumar Prajapati, Rossen Donev
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 9 4 6 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 9 4 7 - 3

FORMTEXT Immunotherapy is emerging as a novel and reliable therapeutic technique for treating diseases such as autoimmunity, HIV/AIDS, allergy and cancers. Immunotherapy change or… Read more

Immunotherapy: Magic Bullet to Change the Future Therapeutics

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

FORMTEXT Immunotherapy is emerging as a novel and reliable therapeutic technique for treating diseases such as autoimmunity, HIV/AIDS, allergy and cancers. Immunotherapy change or modulate our immune system functionalization and activate it to kill pathogen infected cells or affected cells. Development in the field of Immunology, Molecular Biology, and Pharmaceutical Sciences empower the immune system for protecting us agaist number of pathogenic infections. This volume consisit of the chapters from the different stalwarts of the field coveriing the topic such as Immunotherapy past and present, Oncolytic virus based therapy, CAR-T cell therapy, antibody engineering, adjuvant engineering etc. Chapters covered in this volume discuss the immunological translational research in the field of human cancer, parasitic and infectiouds diseases. This volume incudes the chapter describing the tools developed by scientist to engineers safe and effective antibody which can be used as powerful medicine durig human disease conditions. This volume will reflect the secret of biological sciences and technology in the field on immunology to develop safe and efficacious immune molecules based magic bullet to provide absolute cure. This volume will be helpful to the early career researchers and students working in the field of basic and applied immunological sciences.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Chapter One: From past to present: The evolution of immunotherapy and its modern modalities
Abstract
1 Introduction
2 Techniques involved in immunotherapy
3 Conclusions and future perspectives
Acknowledgements
References
Chapter Two: Navigating the landscape: A comprehensive overview of computational approaches in therapeutic antibody design and analysis
Abstract
1 Introduction
2 Computational tools and approaches for designing and analyzing therapeutic antibodies
3 Machine learning and deep learning approaches in therapeutic antibody design and analysis
4 Systems biology and network analysis approaches in therapeutic antibody development
5 Immuno-informatics approaches for developing therapeutic antibodies
6 Integrative approaches for designing and analyzing therapeutic antibodies
7 Enhancing the affinity of a nanobody through an integrated computational approach
8 Conclusion
Acknowledgments
References
Chapter Three: Reconfiguring the immune system to target cancer: Therapies based on T cells, cytokines, and vaccines
Abstract
1 Introduction
2 Overview of T cell-based therapies
3 Cytokine cell-based therapies: an overview
4 Vaccination based immunotherapies
5 Conclusion and future perspectives
Acknowledgments
References
Chapter Four: Monoclonal antibodies – A repertoire of therapeutics
Abstract
1 Antibodies, discovery to therapeutics: a brief history
2 Introduction to B-cells and antibody structure
3 Engineered repertoire of antibodies & immunotherapy
References
Chapter Five: From infection to remedy: Harnessing oncolytic viruses in cancer treatment
Abstract
Abbreviations
1 Introduction
2 Overview on potential use of genetically modified viruses
3 Oncolytic viruses –Development of OVs and modus operandi in tumours
4 Common OVs in practise
5 Outcome of case studies
6 Challenges, limitations and addendums
7 Future perspectives
8 Conclusion
Acknowledgements
References
Chapter Six: Exploring immunotherapy with antibody-drug conjugates in solid tumor oncology
Abstract
1 Introduction
2 Overview of solid tumors
3 Challenges in current cancer treatment approaches
4 Introduction to antibody drug conjugates (ADCs)
5 ADCs as novel immunotherapy for solid tumors
6 Clinical landscape of approved ADCs for solid tumor oncology
7 Mechanisms of most commonly used ADCs in solid tumor treatment
8 Challenges with ADCs
9 Future perspectives & conclusion
Acknowledgments
References
Chapter Seven: From antibodies to nanobodies: The next frontier in cancer theranostics for solid tumors
Abstract
1 Introduction
2 Structural features of nanobodies
3 Nanobodies in the diagnosis and prognosis of solid tumors
4 Nanobodies as therapeutic agents for the treatment of solid tumors
5 Future perspectives
References
Chapter Eight: Revolutionizing pancreatic cancer treatment with CAR-T therapy
Abstract
Abbreviations
1 Introduction
2 Pancreatic cancer (PC)
3 Mutation generated in pancreatic cells leading to cancer
4 Antigens expressed on PC cells as targets for CAR T therapy
5 The tumor microenvironment in PDAC
6 CAR-T cell therapy: a promising therapeutic approach
7 Challenges and limitations of CAR-T cell therapy in pancreatic cancer
8 Future advancements
9 Conclusion
Acknowledgments
References
Chapter Nine: Host directed immunotherapy for chronic infections and cancer
Abstract
1 Introduction
2 Alteration of immune system in chronic diseases
3 Host directed immunotherapies for malaria, leishmaniasis and TB
4 Host directed immunotherapies for cancer
5 Concluding remarks
References
Chapter Ten: Exploring immunotherapy to control human infectious diseases
Abstract
1 Introduction
2 Immunotherapeutic approaches to control human infectious diseases
3 Applications of immunotherapy in bacterial infections
4 Applications of immunotherapy in viral infections
5 Applications of immunotherapy in fungal infections
6 Application of immunotherapy in parasitic infections
7 Conclusion
Acknowledgments
References
Chapter Eleven: Immunotherapy to CD5, a T-cell antigen having roles from development to peripheral function: Future prospective and challenges
Abstract
1 Introduction to immunotherapy where cell surface regulators are targeted
2 CD5: a pan-T-cell marker
3 Pathobiology of mCD5
4 Inhibition of CD5
5 Future aspect
References
Chapter Twelve: Immunotherapy in the management of inflammatory bone loss in osteoporosis
Abstract
1 Introduction
2 Osteoimmunology: Evolving concepts
3 Immunopathogenesis of bone erosion in skeletal diseases
4 Conclusion and future outlook
Acknowledgment
References

Vijay Kumar Prajapati

Dr. Vijay Kumar Prajapati is working as an Associate Professor at Department of Biochemistry, University of Delhi South Campus, New Delhi, India. He has extensive experience in the field of Cell-death Research, Parasitology and therapeutic developments for infectious diseases. He has published more than 100 research articles in the international journal with >20 book chapters with reputed publishers. He is a recipient of prestigious INSA Medal for Young Scientist from Indian National Science Academy (INSA) and Associate from Indian Academy of Sciences, Benguluru. He has published research work in the prestigious journal such as Journal of Infectious Diseases, Clinical Infectious Diseases, Scientific Reports, Medicinal Research Review, Journal of Cellular Physiology etc. His current h-index is 43 with more than 6000 citations.

Affiliations and expertise

Department of Biochemistry, University of Delhi South Campus, India

Rossen Donev

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Affiliations and expertise

Head of Research, MicroPharm Limited, UK

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health